{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T09:24:33Z","timestamp":1789809873473,"version":"4.0.1"},"reference-count":104,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.clml.2015.02.035","type":"journal-article","created":{"date-parts":[[2015,8,18]],"date-time":"2015-08-18T16:14:12Z","timestamp":1439914452000},"page":"S120-S128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"special_numbering":"S","title":["Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia"],"prefix":"10.1016","volume":"15","author":[{"given":"Simona","family":"Soverini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"de Benedittis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Martinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2015.02.035_bib1","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.035_bib2","first-page":"85","article-title":"Chromosome studies on normal and leukemic human leukocytes","volume":"25","author":"Nowell","year":"1960","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clml.2015.02.035_bib3","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.clml.2015.02.035_bib4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/0168-9525(93)90209-Z","article-title":"The multistep nature of cancer","volume":"9","author":"Vogelstein","year":"1993","journal-title":"Trends Genet"},{"key":"10.1016\/j.clml.2015.02.035_bib5","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V58.1.158.158","article-title":"Evidence for a multistep pathogenesis of chronic myelogenous leukemia","volume":"58","author":"Fialkow","year":"1981","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib6","first-page":"1163","article-title":"Further evidence for the existence of a clonal Ph-negative stage in some cases of Ph-positive chronic myelocytic leukemia","volume":"7","author":"Raskind","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.035_bib7","doi-asserted-by":"crossref","first-page":"3118","DOI":"10.1182\/blood.V86.8.3118.3118","article-title":"Detection of major bcr-abl gene expression at a very low level in blood cells of some healthy individuals","volume":"86","author":"Biernaux","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib8","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","article-title":"The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease","volume":"92","author":"Bose","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jmoldx.2010.10.009","article-title":"Common leukemia- and lymphoma-associated genetic aberrations in healthy individuals","volume":"13","author":"Song","year":"2011","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.clml.2015.02.035_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.clml.2015.02.035_bib11","doi-asserted-by":"crossref","first-page":"6649","DOI":"10.1073\/pnas.87.17.6649","article-title":"Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR\/ABL","volume":"87","author":"Kelliher","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.035_bib12","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/j.1460-2075.1990.tb08212.x","article-title":"BCR-ABL, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice","volume":"9","author":"Elefanty","year":"1990","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2015.02.035_bib13","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/14737140.8.6.853","article-title":"Imatinib mesylate for the treatment of chronic myeloid leukemia","volume":"8","author":"Soverini","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clml.2015.02.035_bib14","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib15","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib16","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.1182\/blood-2011-01-328294","article-title":"Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis","volume":"117","author":"Marzocchi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib17","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.2217\/pgs.12.103","article-title":"Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis","volume":"13","author":"Soverini","year":"2012","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clml.2015.02.035_bib18","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11899-013-0194-x","article-title":"Genetic events other than BCR-ABL1","volume":"9","author":"Neviani","year":"2014","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2015.02.035_bib19","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","article-title":"Cytogenetic and molecular genetic evolution of chronic myeloid leukemia","volume":"107","author":"Johansson","year":"2002","journal-title":"Acta Haematol"},{"key":"10.1016\/j.clml.2015.02.035_bib20","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","article-title":"Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.02.035_bib21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clml.2015.02.035_bib22","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1634\/theoncologist.2010-0388","article-title":"Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC(5)(0)?","volume":"16","author":"Soverini","year":"2011","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2015.02.035_bib23","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3324\/haematol.10822","article-title":"Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain","volume":"92","author":"Soverini","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.035_bib24","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1200\/JCO.2006.08.9128","article-title":"Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia","volume":"24","author":"Soverini","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.035_bib25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1470-2045(07)70078-5","article-title":"Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL","volume":"8","author":"Soverini","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2015.02.035_bib26","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.035_bib27","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations","volume":"114","author":"Muller","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib28","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib29","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in\u00a0vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib30","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1182\/blood-2007-06-096396","article-title":"In\u00a0vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib","volume":"111","author":"Khorashad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib31","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2015.02.035_bib32","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1200\/JCO.2008.19.8853","article-title":"Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR\/ABL mutants","volume":"27","author":"Redaelli","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.035_bib33","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1182\/blood-2011-05-355594","article-title":"Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib34","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.clml.2015.02.035_bib35","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2015.02.035_bib36","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib37","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib38","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2013.09.006","article-title":"The next-generation sequencing revolution and its impact on genomics","volume":"155","author":"Koboldt","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.clml.2015.02.035_bib39","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nm1437","article-title":"Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing","volume":"12","author":"Thomas","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2015.02.035_bib40","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s00439-010-0801-z","article-title":"Ultra deep sequencing detects a low rate of mosaic mutations in tuberous sclerosis complex","volume":"127","author":"Qin","year":"2010","journal-title":"Hum Genet"},{"key":"10.1016\/j.clml.2015.02.035_bib41","doi-asserted-by":"crossref","first-page":"8359","DOI":"10.1128\/JVI.02582-10","article-title":"Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants","volume":"85","author":"Gianella","year":"2011","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.clml.2015.02.035_bib42","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2144\/000113733","article-title":"Minor variant detection in amplicons using 454 massive parallel pyrosequencing: experiences and considerations for successful applications","volume":"51","author":"Vandenbroucke","year":"2011","journal-title":"Biotechniques"},{"key":"10.1016\/j.clml.2015.02.035_bib43","doi-asserted-by":"crossref","first-page":"E404","DOI":"10.1111\/j.1469-0691.2012.03951.x","article-title":"Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing","volume":"18","author":"Ko","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clml.2015.02.035_bib44","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1373\/clinchem.2011.176198","article-title":"COLD-PCR enrichment of rare cancer mutations prior to targeted amplicon resequencing","volume":"58","author":"Milbury","year":"2012","journal-title":"Clin Chem"},{"key":"10.1016\/j.clml.2015.02.035_bib45","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1128\/JCM.01723-13","article-title":"Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity","volume":"51","author":"Gong","year":"2013","journal-title":"J\u00a0Clin Microbiol"},{"key":"10.1016\/j.clml.2015.02.035_bib46","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood-2013-03-487728","article-title":"Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib47","article-title":"Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase","author":"Machova Polakova","year":"2014","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2015.02.035_bib48","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3324\/haematol.2010.030999","article-title":"Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy","volume":"96","author":"Hanfstein","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.035_bib49","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.380.380","article-title":"Ultra deep sequencing (UDS) allows more sensitive detection of tyrosine kinase inhibitor (TKI)-resistant BCR-ABL mutations that would influence therapeutic decision at the time of switchover to second- or third-line therapy","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib50","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1172\/JCI30890","article-title":"Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency","volume":"117","author":"Shah","year":"2007","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2015.02.035_bib51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib52","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1073\/pnas.1321173111","article-title":"Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy","volume":"111","author":"Gibbons","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.035_bib53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1182\/blood-2014-05-573485","article-title":"Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination","volume":"124","author":"Parker","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib54","doi-asserted-by":"crossref","first-page":"9530","DOI":"10.1073\/pnas.1105422108","article-title":"Detection and quantification of rare mutations with massively parallel sequencing","volume":"108","author":"Kinde","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.035_bib55","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.035_bib56","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11899-012-0114-5","article-title":"Genetic mechanisms of chronic myeloid leukemia blastic transformation","volume":"7","author":"Skorski","year":"2012","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2015.02.035_bib57","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Bolton-Gillespie","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib58","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/gcc.20303","article-title":"Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization","volume":"45","author":"Hosoya","year":"2006","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2015.02.035_bib59","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/gcc.20487","article-title":"Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression","volume":"46","author":"Brazma","year":"2007","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2015.02.035_bib60","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2010.20","article-title":"Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.035_bib61","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2009-03-210377","article-title":"SNP array analysis of tyrosine kinase inhibitor-resistant chronic myeloid leukemia identifies heterogeneous secondary genomic alterations","volume":"115","author":"Nowak","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib62","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.cancergen.2011.11.003","article-title":"Single nucleotide polymorphism array-based karyotyping shows sequential genomic changes from monosomy to copy-neutral loss of heterozygosity of chromosome 7 and 20q deletion within a balanced translocation t(14;20) in AML","volume":"204","author":"Huh","year":"2011","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clml.2015.02.035_bib63","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12185-011-0796-9","article-title":"Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate","volume":"93","author":"Nadarajan","year":"2011","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2015.02.035_bib64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.cancergen.2012.08.004","article-title":"Acquired genomic copy number changes in CML patients with the Philadelphia chromosome (Ph+)","volume":"205","author":"Lu","year":"2012","journal-title":"Cancer Genet"},{"key":"10.1016\/j.clml.2015.02.035_bib65","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.leukres.2011.12.021","article-title":"Sequential array comparative genomic hybridization analysis identifies copy number changes during blastic transformation of chronic myeloid leukemia","volume":"36","author":"Lee","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.02.035_bib66","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.1992.tb08213.x","article-title":"Mutations of the p53 tumour suppressor gene in haematologic neoplasms","volume":"81","author":"Mori","year":"1992","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.035_bib67","first-page":"593","article-title":"Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques","volume":"7","author":"Neubauer","year":"1993","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.clml.2015.02.035_bib68","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3109\/10428199309047858","article-title":"Molecular defects associated with the acute phase CML","volume":"11","author":"Serra","year":"1993","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.02.035_bib69","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/(SICI)1098-2264(199801)21:1<2::AID-GCC2>3.0.CO;2-5","article-title":"Molecular alterations in the TP53 gene of peripheral blood cells of patients with chronic myeloid leukemia","volume":"21","author":"Peller","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2015.02.035_bib70","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1182\/blood.V78.12.3259.3259","article-title":"Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia","volume":"78","author":"Ahuja","year":"1991","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib71","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3109\/10428190009059278","article-title":"Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia","volume":"38","author":"Beck","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2015.02.035_bib72","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-07-102533","article-title":"RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance","volume":"111","author":"Roche-Lestienne","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib73","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1182\/blood.V85.8.2013.bloodjournal8582013","article-title":"Homozygous deletions of the p16 tumor-suppressor gene are associated with lymphoid transformation of chronic myeloid leukemia","volume":"85","author":"Sill","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib74","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1365-2141.1995.tb05358.x","article-title":"Involvement of the cyclin-dependent kinase-4 inhibitor (CDKN2) gene in the pathogenesis of lymphoid blast crisis of chronic myelogenous leukaemia","volume":"91","author":"Serra","year":"1995","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2015.02.035_bib75","first-page":"771","article-title":"Expression of cell cycle regulatory genes in chronic myelogenous leukemia","volume":"83","author":"Iolascon","year":"1998","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2015.02.035_bib76","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood.V86.1.311.bloodjournal861311","article-title":"p16INK4A and p15INK4B gene deletions in primary leukemias","volume":"86","author":"Haidar","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib77","first-page":"3931","article-title":"Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia","volume":"59","author":"Nakayama","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2015.02.035_bib78","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.clml.2015.02.035_bib79","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1073\/pnas.0602402103","article-title":"Loss of p53 impedes the antileukemic response to BCR-ABL inhibition","volume":"103","author":"Wendel","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.035_bib80","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1101\/sqb.2008.73.039","article-title":"The INK4-ARF (CDKN2A\/B) locus in hematopoiesis and BCR-ABL-induced leukemias","volume":"73","author":"Williams","year":"2008","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10.1016\/j.clml.2015.02.035_bib81","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1101\/gad.1673908","article-title":"Failure of CDKN2A\/B (INK4A\/B-ARF)-mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL","volume":"22","author":"Mullighan","year":"2008","journal-title":"Genes Dev"},{"key":"10.1016\/j.clml.2015.02.035_bib82","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","article-title":"The biology of CML blast crisis","volume":"103","author":"Calabretta","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib83","doi-asserted-by":"crossref","first-page":"6688","DOI":"10.1073\/pnas.0602030103","article-title":"Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia","volume":"103","author":"Williams","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.035_bib84","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1182\/blood-2011-08-370981","article-title":"Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia","volume":"119","author":"Zhao","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib85","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/j.1460-2075.1994.tb06288.x","article-title":"Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia","volume":"13","author":"Mitani","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.clml.2015.02.035_bib86","first-page":"833","article-title":"The AML1\/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence","volume":"11","author":"Kurokawa","year":"1995","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2015.02.035_bib87","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cancergencyto.2010.05.014","article-title":"Cytogenetic and molecular characterization of double inversion 3 associated with a cryptic BCR-ABL1 rearrangement and additional genetic changes","volume":"201","author":"Toydemir","year":"2010","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.clml.2015.02.035_bib88","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1471-2407-8-193","article-title":"EVI1 activation in blast crisis CML due to juxtaposition to the rare 17q22 partner region as part of a 4-way variant translocation t(9;22)","volume":"8","author":"De Weer","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2015.02.035_bib89","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.exphem.2012.05.007","article-title":"CML cells expressing the TEL\/MDS1\/EVI1 fusion are resistant to imatinib-induced apoptosis through inhibition of BAD, but are resensitized with ABT-737","volume":"40","author":"Shimada","year":"2012","journal-title":"Exp Hematol"},{"key":"10.1016\/j.clml.2015.02.035_bib90","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1182\/blood-2008-08-173963","volume":"114","author":"Iacobucci","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib91","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/leu.2014.99","article-title":"Ikaros transcripts Ik6\/10 and levels of full-length transcript are critical for chronic myeloid leukaemia blast crisis transformation","volume":"28","author":"Wang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.035_bib92","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/ni.2821","article-title":"Loss of Ikaros DNA-binding function confers integrin-dependent survival on pre-B cells and progression to acute lymphoblastic leukemia","volume":"15","author":"Joshi","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2015.02.035_bib93","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/ni.2828","article-title":"Stage-specific control of early B cell development by the transcription factor Ikaros","volume":"15","author":"Schwickert","year":"2014","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2015.02.035_bib94","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1073\/pnas.0711824105","article-title":"Gain-of-function mutation of GATA-2 in\u00a0acute myeloid transformation of chronic myeloid leukemia","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clml.2015.02.035_bib95","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.leukres.2009.02.025","article-title":"GATA-2 L359 V mutation is exclusively associated with CML progression but not other hematological malignancies and GATA-2 P250A is a novel single nucleotide polymorphism","volume":"33","author":"Zhang","year":"2009","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2015.02.035_bib96","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/leu.2010.236","article-title":"IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis","volume":"25","author":"Soverini","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.035_bib97","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A\u00a0deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.035_bib98","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib99","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.clml.2015.02.035_bib100","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in\u00a0normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.clml.2015.02.035_bib101","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2015.02.035_bib102","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/leu.2011.155","article-title":"The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories","volume":"25","author":"Kohlmann","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2015.02.035_bib103","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.743.743","article-title":"The Interlaboratory Robustness Of Next-Generation Sequencing (IRON) Study Phase II: Deep-Sequencing Analyses Of Hematological Malignancies Performed In 8,867 Cases By An International Network Involving 27 Laboratories","volume":"122","author":"Kohlmann","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2015.02.035_bib104","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-03-487728","volume":"122","author":"Soverini","year":"2013","journal-title":"Blood"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000798?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265015000798?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,7]],"date-time":"2020-09-07T08:57:55Z","timestamp":1599469075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265015000798"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":104,"alternative-id":["S2152265015000798"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.035","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2015.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}